FIELD: pharmaceuticals.
SUBSTANCE: invention refers to pharmacogenetics and personalized medicine. Disclosed is a method of analysing polymorphous markers in the SLCO1B1, APOE and ABCB1 genes to determine individual sensitivity to statins, comprising the following steps: amplification by multiplex single-step PCR, providing a biochip, hybridising the fluorescent labeled PCR product on the biochip and recording and interpreting the hybridisation results.
EFFECT: invention provides detecting the following polymorphous markers: SLCO1B1 (rs4149056, rs4149015), APOE (rs7412), ABCB1 (rs2032582).
1 cl, 2 dwg, 2 tbl, 4 ex
Authors
Dates
2019-07-26—Published
2018-12-28—Filed